RCC I/II update

  • 09:01

Immunicum AB (publ) today announced continued data improvement from the follow-up phase of a phase I/II-trial in eleven patients with metastatic kidney cancer that started in February 2012. Six patients are still alive and the data show an ongoing, close to doubled median overall survival for the entire patient group and an ongoing right now tripled median overall survival for patients with poor prognosis compared to published historical data for newly diagnosed patients who received standard treatment.

Read the press release here: Press release 151117 – RCC I-II update